Phase II study of Bortezomib, Adriamycin and Dexamethasone (PAD) therapy for previously untreated patients with multiple myeloma: Impact of minimal residual disease (MRD) in patients with deferred ASCT (PADIMAC).

Trial Profile

Phase II study of Bortezomib, Adriamycin and Dexamethasone (PAD) therapy for previously untreated patients with multiple myeloma: Impact of minimal residual disease (MRD) in patients with deferred ASCT (PADIMAC).

Completed
Phase of Trial: Phase II

Latest Information Update: 11 Jul 2017

At a glance

  • Drugs Bortezomib (Primary) ; Dexamethasone; Doxorubicin
  • Indications Multiple myeloma
  • Focus Therapeutic Use
  • Acronyms PADIMAC
  • Most Recent Events

    • 25 Jun 2017 Primary endpoint (2-year PFS for patients who, having achieved CR/VGPR following PAD therapy, do not receive any further treatment) has not been met, according to the abstract presented at the 22nd Congress of the European Haematology Association.
    • 25 Jun 2017 Results presented at the 22nd Congress of the European Haematology Association.
    • 02 Apr 2015 Status changed from active, no longer recruiting to completed as per ISRCTN: Current Controlled Trials.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top